Abstract
Cytogenetic studies were performed as part of all diagnostic and surveillance bone marrow examinations in 956 newly diagnosed patients with multiple myeloma (MM) receiving total therapy (TT) protocols and in 1085 previously treated patients enrolled in non-TT protocols. In both groups, cytogenetic abnormalities (CA) were present in one-third at baseline and persisted in 14% prior to first and 10% prior to second transplant (TT, 5%; non-TT, 15%); post-transplant detection rates increased progressively with time, from 7% within 6 months to 21% within 24 months to 28% at relapse. According to multivariate analyses, overall survival was adversely affected by the presence of CA at baseline (hazard ratio (HR)=7.20, P<0.001) and the development of CA both prior to (HR=3.28, P<0.001) and after first transplant (HR=6.24, P<0.001), whereas suppression of CA pretransplant was favorable (HR=0.38, P<0.001). The presence of CA at relapse further distinguished patients with a short median post-relapse survival of only 11 versus 47 months in those without CA (P<0.0001). Post-relapse survival was independently adversely affected by the detection of CA both at baseline (HR=1.35, P=0.044) and relapse (HR=2.47, P<0.001). Collectively, these result...Continue Reading
References
Aug 1, 1985·The Journal of Clinical Investigation·B BarlogieL Smith
Jul 1, 1995·Cancer Genetics and Cytogenetics·J R SawyerB Barlogie
Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G TricotB Barlogie
May 12, 1998·British Journal of Haematology·C SeongR Alexanian
Feb 14, 2002·British Journal of Haematology·Guido TricotBart Barlogie
Dec 21, 2002·British Journal of Haematology·John ShaughnessyBart Barlogie
Jan 18, 2003·Blood·John ShaughnessyBart Barlogie
Jul 25, 2003·British Journal of Haematology·Joth JacobsonJeff Sawyer
Mar 3, 2004·Cancer Research·Rafael FonsecaHerve Avet-Loiseau
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Aug 31, 2006·British Journal of Haematology·Bart BarlogieJohn Crowley
Nov 16, 2006·Blood·John D ShaughnessyBart Barlogie
Apr 10, 2007·Blood·Frits van RheeBart Barlogie
May 11, 2007·British Journal of Haematology·John D ShaughnessyBart Barlogie
Jun 27, 2007·British Journal of Haematology·Bart BarlogieJohn D Shaughnessy
Sep 27, 2007·Blood·Bart BarlogieJeffrey Sawyer
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey HaesslerBart Barlogie
Feb 27, 2008·Cancer·Mauricio Pineda-RomanJohn Crowley
Feb 28, 2008·British Journal of Haematology·Mauricio Pineda-RomanBart Barlogie
May 22, 2008·Blood·Bart BarlogieJohn Crowley
Citations
Jul 3, 2013·Leukemia Research·Daryl TanJae Hoon Lee
Feb 16, 2010·Bone Marrow Transplantation·D TanW Hwang
Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Aug 8, 2008·Leukemia·P G RichardsonK C Anderson
May 5, 2012·European Journal of Haematology·Daryl TanWee J Chng
Aug 20, 2010·American Journal of Hematology·Daryl TanY T Goh
Mar 25, 2010·European Journal of Haematology·Massimo OffidaniPiero Galieni
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerAlan S Wayne
Dec 17, 2008·Hematology·Jean-Luc Harousseau
Mar 31, 2016·European Journal of Haematology·Laurens E FranssenNiels W C J van de Donk
Apr 17, 2008·Leukemia·P L Bergsagel
Feb 29, 2008·Leukemia·B BarlogieJ Crowley
May 23, 2020·Blood Advances·Patrick W MellorsShaji K Kumar
Nov 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yogesh S JethavaFrits van Rhee